Abstract
Primary hyperparathyroidism is the main endocrinopathy associated with Multiple Endocrine Neoplasia type 1 syndrome. Cinacalcet is a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease, and for the reduction of marked hypercalcemia in patients with parathyroid carcinoma and sporadic hyperparathyroidism requiring surgery but for whom parathyroidectomy is contraindicated. It may provide a medical alternative for the management of primary hyperparathyroidism in subjects affected by Multiple Endocrine Neoplasia type 1. In this longitudinal, intervention study, 33 MEN1 patients had been enrolled, 10 males and 23 females with a mean age of 40 ± 11.9 years, range 20–63. Primary hyperparathyroidism was the first clinical manifestation in 12 patients. All subjects commenced with Cinacalcet 30 mg/day, 22 patients starting therapy with calcimimetics as an alternative to surgery, and 11 patients opting for the medication after the onset of persistent post-surgical primary hyperparathyroidism. Duration of follow-up was 12 months. The results of this study show significant reductions in serum calcium. The changes in hormonal secretions of pituitary and gastroenteropancreatic glands were not significant, demonstrating the overall safety of this drug in this disease. Cinacalcet has been well tolerated by 28 patients, whereas five individuals complained of heartburn and grade 1 nausea, which did not prevent the completion of the study. In conclusion, Cinacalcet has resulted to be well tolerated and safe in patients with MEN1 syndrome and the calcium homeostasis was stabilized.
Similar content being viewed by others
References
M.L. Brandi, R.F. Gagel, A. Angeli et al., Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658 (2001)
R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990 (2012)
Giusti, F., Marini, F., Brandi, M. L.: Multiple endocrine neoplasia type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997–2005. http://www.ncbi.nlm.nih.gov/books/NBK1538; initial posting: August 31, 2005; last updated: September 6, 2012
T. Carling, R. Udelsman, Parathyroid surgery in familial hyperparathyroid disorders. J. Intern. Med. 257, 27 (2005)
F. Tonelli, T. Marcucci, G. Fratini, M.S. Tommasi, A. Falchetti, M.L. Brandi, Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann. Surg. 246, 1075 (2007)
D.M. Elaraj, M.C. Skarulis, S.K. Libutti, J.A. Norton, D.L. Bartlett, J.F. Pingpank, F. Gibril, L.S. Weinstein, R.T. Jensen, S.J. Marx, H.R. Alexander, Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 134, 858 (2003)
E.M. Brown, The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell. Biochem. 45, 139 (2007)
E.F. Nemeth, M.E. Steffey, L.G. Hammerland, B.C. Hung, B.C. Van Wagenen, E.G. DelMar, M.F. Balandrin, Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA 95, 4040 (1998)
E.F. Nemeth, J. Fox, Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 10, 66 (1999)
J.S. Lindberg, S.M. Moe, W.G. Goodman, J.W. Coburn, S.M. Sprague, W. Liu, P.W. Blaisdell, R.M. Brenner, S.A. Turner, K.J. Martin, The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 63, 248 (2003)
L.D. Quarles, D.J. Sherrard, S. Adler, S.J. Rosansky, L.C. McCary, W. Liu, S.A. Turner, D.A. Bushinsky, The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Jam Soc Nephrol 14, 575 (2003)
D.M. Shoback, J.P. Bilezikian, S.A. Turner, L.C. McCary, M.D. Guo, M. Peacock, The calcimimetic Cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88, 5644 (2003)
M. Peacock, J.P. Bilezikian, P.S. Klassen, M.D. Guo, S.A. Turner, D. Shoback, Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. J. Clin. Endocrinol. Metabol. 90, 135 (2005)
A. Khan, J. Bilezikian, H. Bone, A. Gurevich, P. Lakatos, W. Misiorowski, L. Rozhinskaya, M.L. Trotman, M. Tóth, Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur. J. Endocrinol. 172, 527 (2015)
European Medicines Agency, Assessment report for cinacalcet (Mimpara®), Procedure No. EMEA/H/C/000570/II/0010: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000570/WC500028903.pdf (2008)
Federal Drug Administration (FDA), Report for cinacalcet (Sensipar®): http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021688s017lbl.pdf (2011)
FDA drug safety communivìcation: http://www.fda.gov/Drugs/DrugSafety/ucm340551.htm
EMA, cinacalcet, Annex I, summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000570/WC500028900.pdf (2013)
J.A. Balfour, L.J. Scott, Cinacalcet hydrochloride. Drugs 65, 271 (2005)
M.S. Joy, A.V. Kshirsagar, N. Franceschini, Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann. Pharmacother. 38, 1871 (2004)
A. Falchetti, A. Cilotti, L. Vagelli, L. Masi, A. Amedei, F. Cioppi, F. Tonelli, M.L. Brandi, A patient with MEN1-associated hyperparathyroidism, responsive to Cinacalcet. Nat. Clin. Pract. Endocrinol. Metab. 4, 351 (2008)
V.J. Moyes, J.P. Monson, S.L. Chew, S.A. Akker, Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int. J. Endocrinol. 2010, 906163 (2010)
M. Filopanti, U. Verga, F. Ermetici, L. Olgiati, C. Eller-Vainicher, S. Corbetta, L. Persani, P. Beck-Peccoz, A. Spada, MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur. J. Endocrinol. 167, 157 (2012)
F. Saponaro, A. Faggiano, F. Grimaldi, G. Borretta, M.L. Brandi, S. Minisola, A. Frasoldati, E. Papini, A. Scillitani, C. Banti, M. Del Prete, F. Vescini, L. Gianotti, L. Cavalli, E. Romagnoli, A. Colao, F. Cetani, C. Marcocci, Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin. Endocrinol. 79, 20 (2013)
C. Marcocci, J. Bollerslev, A.A. Khan, D.M. Shoback, Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. 99, 3607 (2014)
C. Ho, D.A. Conner, M.R. Pollak, D.J. Ladd, O. Kifor, H.B. Warren, E.M. Brown, J.G. Seidman, C.E. Seidman, A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11, 389 (1995)
M. Colloton, E. Shatzen, G. Miller, C. Stehman-Breen, M. Wada, D. Lacey, D. Martin, Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 67, 467 (2005)
T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, Y. Nishizawa, Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur. J. Endocrinol. 153, 587 (2005)
N. Wettschureck, E. Lee, S.K. Libutti, S. Offermanns, P.G. Robey, A.M. Spiegel, Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+-sensing receptor. Mol. Endocrinol. 21, 274 (2007)
Y. Imanishi, M. Inaba, T. Kawata, Y. Nishizawa, Animal models of hyperfunctioning parathyroid diseases for drug development. Exp. Opin. Drug Discov. 4, 727 (2009)
K. Weber, C. Bergow, S. Hirmer, C. Schüler, R.G. Erben, Vitamin D-independent therapeutic effects of extracellular calcium in a mouse model of adult-onset secondary hyperparathyroidism. J. Bone Miner. Res. 24, 22 (2009)
Y. Imanishi, T. Kawata, T. Kenko, M. Wada, N. Nagano, T. Miki, A. Arnold, M. Inaba, Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif. Tissue Int. 89, 29 (2011)
M.N. Hodgkin, C.E. Hills, P.E. Squires, The calcium-sensing receptor and insulin secretion: a role outside systemic control 15 years on. J. Endocrinol. 199, 1 (2008)
J. Parkash, Inflammatory cytokine signaling in insulin producing beta-cells enhances the colocalization correlation coefficient between L-type voltage-dependent calcium channel and calcium-sensing receptor. Int. J. Mol. Med. 22, 155 (2008)
I. Kitsou-Mylona, C.J. Burns, P.E. Squires, S.J. Persaud, P.M. Jones, A role for the extracellular calcium-sensing receptor in cell-cell communication in pancreatic islets of langerhans. Cell. Physiol. Biochem. 22, 557 (2008)
D. Haid, P. Widmayer, H. Breer, Nutrient sensing receptors in gastric endocrine cells. J. Mol. Histol. 42, 355 (2011)
J.M. Ray, P.E. Squires, S.B. Curtis, M.R. Meloche, A.M. Buchan, Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J. Clin. Invest. 99, 2328 (1997)
R. Mamillapalli, J. Wysolmerski, The calcium-sensing receptor couples to Galpha(s) and regulates PTHrP and ACTH secretion in pituitary cells. J. Endocrinol. 204, 287 (2010)
M. Peacock, M.A. Bolognese, M. Borofsky, S. Scumpia, L.R. Sterling, S. Cheng, D. Shoback, Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 94, 4860 (2009)
V. Ramundo, M. Del Prete, V. Marotta, F. Marciello, L. Camera, V. Napolitano, L. De Luca, L. Circelli, V. Colantuoni, A. Di Sarno, A.C. Carratù, C. de Luca di Roseto, A. Colao, A. Faggiano, Multidisciplinary Group for Neuroendocrine Tumors of Naples: Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin. Endocrinol. 80, 850 (2014)
Acknowledgments
This study was supported by an unrestricted grant from Amgen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All Authors have no conflict of interest to declare regarding this paper. More general disclosures for P.F.: Advisory Board for Novartis, Ipsen, Lexicon, and Italfarmaco. More general disclosures for M.L.B.: consultant and grants from Alexion, Abiogen, Amgen, Bruno Farmaceutici, Eli Lilly, MSD, NPS, Shire, SPA, and Servier.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Giusti, F., Cianferotti, L., Gronchi, G. et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine 52, 495–506 (2016). https://doi.org/10.1007/s12020-015-0696-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0696-5